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Abstract
The spread of methicillin-resistant Staphylococcus aureus is continuous. The emergence of community-acquired methicillin-resistant
S. aureus (CA-MRSA) was rapidly followed by its introduction into and dissemination in hospitals in countries where CA-MRSA
prevalence is high. Vancomycin-resistant enterococci have recently been responsible for outbreaks in European hospitals in relation to
dissemination of hospital-adapted isolates. Although new antimicrobials have been recently introduced into therapy to ﬁght multidrug-
resistant Gram-positive cocci, resistance to these compounds has already emerged in rare strains. This review presents recent data
concerning the advance of our knowledge related to these problems.
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The major resistance issues concerning Gram-positive
organisms are those related to methicillin-resistant Staphylo-
coccus aureus (MRSA) and glycopeptide-resistant entero-
cocci (GRE). The epidemicity and the means of
dissemination of these microorganisms are incompletely
understood, although progress has been made in decipher-
ing the complex interactions among host, pathogen, and
environment. Progress has also been made with new
molecular methods that show great promise in strengthen-
ing our ability to detect colonization or infection with
these bacteria. Concerns about dissemination of multidrug-
resistant (MDR) bacteria have prompted the licensing of a
few new agents that have, for the most part, narrow spec-
tra of activity, and are focused on Gram-positive patho-
gens. However, resistance to some of these new agents
emerged in rare bacteria as soon as they were introduced
into therapy.
The Routes of MRSA Dissemination
From MRSA nasopharyngeal carriage to infection
S. aureus has the capacity to both colonize human hosts
without causing too much harm and act as a major pathogen.
The role of nasopharyngeal carriage of S. aureus in the
spread of microorganisms, including MDR strains, and as a
risk factor for infection in the host is well documented [1].
Several genomes of S. aureus have now been completely
sequenced. Sequence analysis has shown that all S. aureus
strains contain major virulence factors and that they have
the capacity to become invasive [2]. Staphylococcal virulence
is probably better explained by modulation of the expression
of virulence factors by accessory genes. However, and most
importantly, individual variations in intermittent or persistent
carrier status cannot be understood without identiﬁcation of
host factors that contribute to colonization. The complete
picture of the contribution of host genetic polymorphism to
nasal carriage and the occurrence of infections is far from
being completely elucidated. Recent studies have shown
associations between polymorphisms in interleukin-4, com-
plement factor H and C-reactive protein, on the one hand,
and S. aureus carrier status and the occurrence of boils on
the other [3]. The observation that the host genotype was
associated with carriage of certain staphylococcal types con-
ﬁrms that nasopharyngeal carriage results from complex
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interactions among host, pathogen, and environment, includ-
ing antibiotic selective pressure.
Dissemination of MRSA: tracing the bacteria and identifying
new reservoirs
The spread of MDR bacteria results from an interplay of
transfer of resistance genes between strains, bacterial species
or genera and of dissemination of bacterial clones in various
environments. Gene transfer occurs through horizontal trans-
fer of plasmids, transposition (e.g. vanA borne by transposon
Tn1546 in enterococci), dissemination of resistance cassettes
(e.g. SCCmec in MRSA), or transformation (e.g. pbp genes of
Streptococcus pneumoniae), depending on the microorganism
and on the genetic support of the resistance determinant.
Tools are available for tracing the sources of dissemina-
tion and deciphering the genomic evolution of MDR organ-
isms that allow adaptation to diverse hosts and
environments. Various genotyping techniques based on PCR
(rep-PCR, ampliﬁed fragment length polymorphism), pulsed-
ﬁeld gel electrophoresis, sequencing (multilocus variant
analysis, single-locus sequence typing, multilocus sequence
typing (MLST)) and DNA microarrays may be used.
The choice of the technique will depend on the objectives
of the study, which can be limited to local outbreaks or can
extend to national or global surveillance; this has recently
been discussed by van Belkum et al. [4].
In staphylococci, the mecA gene encoding penicillin-binding
protein 2a, responsible for methicillin resistance, is borne by
21–67-kb mobile genetic elements, termed the staphylococ-
cal cassette chromosome mec (SCCmec) [5]. The SCCmec
element integrates into the S. aureus chromosome at a
unique site (attBSCC). SCCmec elements are characterized
by the presence of ﬂanking terminal direct and, in most
cases, inverted repeats, two essential genetic components
(the mec gene complex and the ccr gene complex), and three
junkyard (or jigsaw) regions (J). To date, six classes (A, B,
C1, C2, D, and E) of mec gene complex and ﬁve types (1, 2,
3, 4, and 5) of ccr gene complex have been described. Differ-
ent combinations of ccr and mec complexes allowed the deﬁ-
nition of six types in S. aureus, with subypes deﬁned as
variations in the J regions [6]. SCCmec typing is used in com-
bination with other typing techniques, such as MLST, for
tracing MRSA clones. Using different typing techniques, in
particular MLST, the spread of hospital-acquired (HA)-MRSA
and community-acquired (CA)-MRSA clones has been traced.
The role of travel and of population migrations in the spread
of MDR organisms is now well established. For instance, in
Belgium, 25% of CA-MRSA infections were acquired after
travel abroad [7]. The origin of new epidemic HA-MRSA
clones is still under discussion. They may result from interna-
tional cross-border spread or de novo emergence of clones
by SCCmec type IV insertion into recipient methicillin-sus-
ceptible S. aureus lineages.
New reservoirs of MRSA have been identiﬁed using MLST
techniques. In The Netherlands, unexpected cases of MRSA
carriage and infection were linked to pig farming [8]. Isolates
belonged to sequence type ST398. This particular type was
found in staphylococci from pigs in France [9], and was highly
prevalent in MRSA isolated in 39% of pigs in slaughterhouses
in The Netherlands [10].
Finally, these powerful typing techniques have shed light
on the circulation, the reservoirs and the origin and evolu-
tion of MDR organisms. However, predictions about future
epidemic MDR clones and evolution remain uncertain.
MRSA strains have abolished borders between the
community and hospitals
As already mentioned, MRSA isolates have spread internation-
ally. However, they have traditionally been associated with
infections in hospitals, to which they were mostly conﬁned.
Recently, new MRSA strains have emerged and rapidly
spread in the community. They cause infections that are
acquired by persons who have not been recently hospitalized
or undergone a medical procedure (related to, for example,
surgery, catheters, percutaneous medical devices, or dialysis).
These so-called CA-MRSA strains are responsible for infec-
tions with a particular clinical presentation, and are associ-
ated with skin and soft tissue infections, such as pimples and
boils, that occur in previously healthy and young persons.
Although there is no consensus deﬁnition, CA-MRSA iso-
lates from throughout the world have several common char-
acteristics. The most important are the production of
Panton–Valentine leukocidin (PVL), which is infrequent in
other S. aureus strains, and the presence of short SCCmec
elements (of type IV or V). CA-MRSA isolates initially lacked
multiple resistance to antibiotics. However, they can be clas-
siﬁed as MDR organisms, because they are resistant to the
b-lactam class of antibiotics, which includes major antistaphy-
lococcal agents, and to some other antimicrobials, such
as tetracyclines and fusidic acid, when isolated in Europe.
In addition, new variants of CA-MRSA clones resistant to
clindamycin and quinolones have recently emerged [11].
In the USA, CA-MRSA became more prevalent than methi-
cillin-susceptible S. aureus in community-acquired S. aureus
infections. In a recent study including 422 emergency depart-
ment patients, 59% of S. aureus isolates from skin and soft tis-
sue infections requiring drainage were resistant to methicillin,
with variations from 20% to 72%, depending upon the state
[12]. Most infections in the USA are due to an MRSA clone
characterized by sequence type ST8 and called USA300.
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Two recent major events in the evolution of the USA300
clone were observed. First, it started to inﬁltrate hospitals
and to replace the traditional HA-MRSA strains. From 2000
to 2006, the proportion of MRSA strains isolated from hos-
pital-onset bloodstream infections and displaying a commu-
nity phenotype of resistance increased from 24% to 49% in a
US hospital [13]. The total number of bloodstream infections
remained stable, suggesting that the CA-MRSA strains
replaced the HA-MRSA strains without causing additional
infections. However, spread of CA-MRSA infections in hospi-
tals is worrying, as it would occur among a more debilitated,
older patient population and would provoke more severe
infections. In addition, the skin tropism may add to the
capacity of CA-MRSA to disseminate, which may eventually
lead to an increased global burden of infections.
Subsequently, variants of USA300 MRSA that were resis-
tant to clindamycin, ciproﬂoxacin and mupirocin became
common among men who have sex with men [14]. Possibly,
MDR MRSA infections will have to be added to the list of
sexually transmitted diseases.
CA-MRSA strains have also been described on other con-
tinents. Clones were initially reported as being continent-
speciﬁc, with the ST80 type spreading in Europe. However,
recent data show intercontinental exchanges of CA-MRSA
clones and emergence of new PVL-positive clones, resulting
in a more complex situation.
The prevalence of CA-MRSA is not uniform in Europe. It
ranges from low in France (3.6% of MRSA) and in England
and Wales [15,16] to high in Greece, with 75% of MRSA
strains in the community containing PVL genes [17]. The
prevalence is also high at the southern boundary of Europe,
with 72% of MRSA strains containing PVL genes in Algeria
[11]. The high prevalence of CA-MRSA in certain countries
was found to be associated with an increased prevalence of
CA-MRSA in hospitals [17] and, in Algeria, with diversiﬁca-
tion of the resistance proﬁles [11].
Despite the recent developments, the European ST80
clone seems to have less potential for dissemination than the
USA300 clone. The epidemiological success of the USA300
clone (which may be considered as a ‘superbug’) has tenta-
tively been explained by several particular characteristics.
USA300 produces novel cytolytic peptides called phenol-sol-
uble modulins that have the capacity to recruit, activate and
subsequently damage human neutrophils [18]. Phenol-soluble
modulin-alpha is rarely detected in HA-MRSA strains.
Recently, the arginine catabolic mobile element was found in
association with the staphylococcal chromosomal cassette
mec in USA300 lineages, but it was absent in most of the
other CA-MRSA isolates, including ST80 [19]. This element
encodes an arginine deiminase pathway and a putative
oligopeptide permease operon (Opp-3). Arginine deiminase
could enhance arginine catabolism and the survival of
USA300 in anaerobic environments. Opp-3 may contribute
to the overall ﬁtness of USA300 by improving growth,
adhesion to host cells, and expression of virulence deter-
minants. The ﬁtness of CA-MRSA may also be inﬂuenced by
the polymorphism of the S. aureus PVL [20].
The possibility should be considered that the USA300
clone that has recently arrived in Europe may replace ST80,
leading to a situation similar to that seen in the USA.
MDR Coagulase-Negative Staphylococci
Staphylococcus epidermidis and other coagulase-negative staph-
ylococci are major constituents of the permanent normal
human ﬂora. Coagulase-negative staphylococci are consid-
ered to be poorly pathogenic for normal hosts, apart from
some species, e.g. Staphylococcus saprophyticus and Staphylo-
coccus lugdunensis, which are responsible for common urinary
tract infections and skin and soft tissue infections, respec-
tively. Isolates belonging to these latter species are usually
susceptible to most antistaphylococcal agents. By contrast,
S. epidermidis and S. haemolyticus often combine resistances
to major antistaphylococcal agents, and are important causes
of material-associated infections.
The ‘virulence’ potential of S. epidermidis relies on the
presence of several surface and surface-associated proteins,
and on the capacity of this microorganism to produce bio-
ﬁlm. Several surface proteins, the so-called MSCRAMMS,
characterized by the presence of LPXTG motifs, have been
identiﬁed in S. epidermidis, including ﬁbrinogen-binding (Fbe)
and collagen-binding (SdrF) proteins, accumulation-associated
protein (Aap), and Bap homologue protein (Bhp). In combi-
nation with surface-associated proteins, such as ﬁbronectin-
binding protein (Embp), collagen-binding protein (GehD), and
adhesins (Aae and AtlE), and the polysaccharide intercellular
adhesin (PIA), these proteins interact at the different steps
of adhesion to surfaces and of the development of bioﬁlm.
AtlE and PIA have been found to be involved in the early
attachment to polymer surfaces, and PIA and Aap play a role
in the proliferation and accumulation of bacterial cells that
form part of the bioﬁlm.
In a European study in intensive-care units, coagulase-neg-
ative staphylococci were found to be the ﬁrst cause of
bloodstram infections (19.4%) and, overall, accounted for
10.5% of infections (fourth most frequent cause of infection)
[21].
The role of coagulase-negative staphylococci in catheter-
related infections, prosthetic joint infections and pacemaker
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endocarditis is well established. As an example, the rate
of intravascular catheter infection has been estimated to be
3–5% in the UK [22]. In addition, these bacteria cause 8% of
cases of native valve endocarditis not associated with drug
use, with a 25% mortality rate, which is similar to that due
to S. aureus [23].
Multidrug resistance is common in S. epidermidis and
even more so in Staphylococcus haemolyticus. Less than 30%
of S. epidermidis isolates circulating in the hospital environ-
ment are susceptible to oxacillin, and only about 40%, 45–
60% and 45% are susceptible to gentamicin, clindamycin and
ciproﬂoxacin, respectively [21,24]. Resistance to glycopep-
tides, usually associated with resistance to methicillin, has
also been reported in S. epidermidis and S. haemolyticus. How-
ever, the inﬂuence of technical factors such as inoculum size,
medium and incubation time on susceptibility tests, and dif-
ferent standards used by the CLSI, EUCAST and other com-
mittees for testing, make the prevalence of glycopeptide
resistance difﬁcult to evaluate. With regard to teicoplanin,
local variations may explain the wide range in rates of resis-
tance, reported to vary from 1.5% [21] to 55% [25]. Vanco-
mycin resistance seems to be rare in coagulase-negative
staphylococci.
In addition to their role as potential pathogens under cer-
tain circumstances, MDR coagulase-negative staphylococci
have been suspected to be providers to S. aureus of mecA
and of other resistance genes. The presence of a mecA-like
gene in all isolates of Staphylococcus sciuri might be taken to
incriminate this species as a major source of mecA [26].
However, S. sciuri is rarely isolated from humans, and the
mecA-like gene displays only 80% identity with mecA. This
argues against a recent transfer of the gene to human staphy-
lococci, but suggests that the S. sciuri gene is the ancestor of
the mecA gene currently spreading among clinical isolates of
S. aureus.
Several observations support the hypothesis of transfer of
methicillin resistance between coagulase-negative staphylo-
cocci and S. aureus. First, a recent study conﬁrmed the high
prevalence of methicillin-resistant coagulase-negative staphy-
lococci in nasal carriers, between 11% and 31% in four coun-
tries (on three continents) [27]. Andremont et al. (personal
communication) found, in a recent unpublished study
conducted in France, that 3.5% of study patients had nasal
co-colonization with methicillin-susceptible S. aureus and
methicillin-resistant coagulase-negative staphylococci, show-
ing that opportunities for mecA gene transfer are not rare.
Molecular studies provided evidence of interspecies transfer
of mec cassetttes. The type IV SCCmec, which is widespread
in MRSA, is the most frequent in S. epidermidis [28]. The
nucleotide sequences of the cassettes in both species were
identical [29]. Notably, S. epidermidis showed a higher diver-
sity of mec cassettes than S. aureus, and new types were
found in recent studies [27,30]. Therefore, S. epidermidis
strains form an abundant reservoir of various SCCmec types
that could subsequently be transferred to S. aureus and other
staphylococcal species. Future emergence of new cassette
types in S. aureus can be conﬁdently predicted.
GRE
Since the 1980s, enterococci have been identiﬁed as an
important cause of nosocomial infections, generally ranking
as the third or fourth most prevalent genus among nosoco-
mial pathogens.
Eighty-ﬁve to 90% of enterococcal infections are due to
Enterococcus faecalis and c. 10% to Enterococcus faecium. In
the latter species, acquisition of resistance is a major cause
of concern. Most prominently, resistance to penicillin–ampi-
cillin, aminoglycosides (high-level resistance), and glycopep-
tides is being reported in an increasing number of isolates,
which limits the therapeutic possibilities.
Glycopeptides act by blocking cell wall formation, and
resistance is due to the synthesis of modiﬁed peptidoglycan
precursors, terminating in D-alanyl-D-lactate or D-alanine-D-
serine. Six types of acquired glycopeptide resistance
(types VanA, B, D, E, G, and L) have been described. The
vanA and vanB resistance genotypes are by far the most pre-
valent in Europe, and are mostly found in E. faecium. GRE
are now highly prevalent in the USA and some Asian coun-
tries. In Europe, the situation is different, with prevalence
ranging from <1% to >40%.
A major concern is the transfer of plasmid-mediated VanA
resistance to MRSA. Seven isolates have been reported in the
USA since 2002 (which were not cross-transmitted to other
patients) [31], one isolate in Iran [32], and another isolate in
India [33]. The risk of emergence of MRSA resistant to vanco-
mycin is highest in countries with a high prevalence of both
MRSA and GRE. This unwelcome perspective has reinforced
the willingness of health authorities in several countries to
make efforts to prevent the further spread of GRE [34].
In Europe, the major reservoir of GRE was initially the
healthy population in the community, 2–10% of whom were
carriers. The source was most likely the GRE reservoir in
animals, where it most likely arose due to the widespread
use of avoparcin (a glycopeptide similar to teicoplanin) as a
growth promoter during the 1980s.
Recently, the epidemiology has changed with the report of
hospital outbreaks, and it now resembles that described
in the USA since the 1990s. A recent review by Werner
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et al. [34] described the emergence and spread of GRE in
Europe.
Deﬁned clonal groups of E. faecium have been identiﬁed
using DNA sequence-based typing (MLST) and phylogenetic
analyses [35]. The clones that have been grouped in a sup-
erclonal complex called CC17 are mostly ampicillin-resistant
and high-level ciproﬂoxacin-resistant, and show an enhanced
capacity to disseminate in the nosocomial setting. These
clones have been circulating in hospitals for 20 years, but
acquired transferable glycopeptide resistance only recently.
They possess additional genomic material, which includes a
pathogenicity island bearing a putative virulence gene for an
enterococcal surface protein, esp, and genes encoding differ-
ent cell wall-anchored surface proteins, a putative hyaluroni-
dase gene, hylEfm, and a gene encoding a collagen-binding
protein, acm [36]. Also, DNA microarray studies showed
that E. faecium CC17 contains a much larger accessory gen-
ome than non-hospital isolates [37].
Although there are now numerous data from population
analysis, the reasons for the rise of GRE in Europe since
2004 have remained unknown. The bases of the epidemicity
of E. faecium CC17 are incompletely elucidated. However,
it has been learned from hospitals facing GRE outbreaks that
spread can be successfully stopped by immediate infection
control measures, including extensive and rapid screening of
GRE carriers [38].
Infection Control Programmes Proﬁt from
New Bacteriological Techniques
Culture-based and nucleic acid-based detection methods for
major MDR Gram-positive organisms in carriers or infected
patients have greatly improved during the last 10 years. The
techniques apply to only a few, but important, organism–anti-
microbial agent combinations, allowing identiﬁcation in a sin-
gle step of the bacterial species and of major antibiotic
resistance characteristics. MRSA and GRE, which are often
multiply resistant to other antimicrobials, are relevant targets
for these techniques [39].
Whereas conventional methods required 2–4 days for the
detection of MRSA and GRE, new chromogenic media have
the potential to produce results within 24 h. Most chromo-
genic media show high speciﬁcities after 24 h of incubation,
with no necessity for conﬁrmatory tests; however, sensitivities
vary widely, from 50% to 99%, depending on multiple factors.
Pre-enrichment results in a substantial increase in sensitivity,
but may increase the time required to obtain results. The best
balance between rapid results and increased sensitivities, in
terms of impact on infection control, has still to be found.
Several nucleic acid-based methods have been developed
for the detection of MRSA. Those that are based on hybrid-
ization can be performed only with bacterial cultures.
A major advantage of these techniques is the rapid identiﬁca-
tion of MRSA in positive blood cultures, where 96–100%
agreement with phenotypic techniques is obtained [40].
Ampliﬁcation-based techniques may be carried out with iso-
lates, with blood cultures and, most interestingly for preven-
tion of cross-transmission of MDR bacteria, with screening
samples. Commercial tests are now available with sensitivities
and negative predictive values that are equivalent to or slightly
better than those obtained with culture. Therefore, these
tests can be used to justify the removal of patients from isola-
tion. However, positive results still require conﬁrmation.
Chromogenic media and molecular techniques are also
available for the detection of vancomycin-resistant entero-
cocci. PCR-based techniques are used for species conﬁrma-
tion and characterization of vancomycin resistance genes of
isolates from cultures, e.g. stool cultures and enrichment
broths, and also directly from rectal swabs.
Again, the negative and positive predictive values are use-
ful in screening programmes, and may help to control the
rapid diffusion of GRE from patient to patient.
However, molecular methods allow detection only of
known mechanisms of resistance and, so far, do not apply to
cases where resistance is due to deregulation of gene
expression. For instance, no molecular method is available
for the detection and identiﬁcation of glycopeptide-interme-
diate S. aureus (GISA), where resistance is not due to speciﬁc
genes but to the alteration of expression of multiple genes
involved in cell wall synthesis.
If it is clear that the excellent negative predictive values of
most rapid molecular techniques may save a large number of
unnecessary isolation days in screening programmes. How-
ever, the high cost of these techniques prevents their wide-
spread use. In addition, there is no single and stand-alone
rapid assay that can recognize a large variety of MDR organ-
isms in clinical samples. More studies are needed to demon-
strate the medical and economic beneﬁts of control strategies
using the molecular tools. Probably, these techniques are par-
ticularly useful for the management of outbreaks.
Resistance to Old and New Antimicrobial
Agents
Staphylococci with diminished susceptibility to
glycopeptides
Vancomycin is still the alternative to oxacillin in cases
of resistance (or intolerance). The deﬁnitions and clinical
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consequences of diminished susceptibility to vancomycin
remain controversial. Different standards used by national
committees for antibiotic susceptibility testing and lack of a
genetic reference technique make difﬁcult the identiﬁcation
of GISA strains and even more of heterointermediate GISA
(hGISA) strains, which appear to be susceptible to vancomy-
cin but consist of subpopulations of intermediate susceptibil-
ity to this glycopeptide [41]. Although the population analysis
proﬁle, and in particular the population analysis proﬁle/AUC
ratio, became the reference technique, it cannot be easily
applied routinely in clinical microbiology laboratories [42].
GISA and hGISA share thickened cell walls, reduced pepti-
doglycan cross-linking, and reduced autolytic activity. They
display higher MICs than fully vancomycin-susceptible
S. aureus [43].
The prevalence of hGISA has been evaluated in several
studies, and is higher among MRSA strains (c. 2%) than
among methicillin-susceptible S. aureus strains (0.05%) [44].
The clinical impact of diminished susceptibility to vanco-
mycin has been evaluated in several studies. However, in
most cases studied, isolates were obtained during the late
stages of vancomcyin therapy. In addition, vancomycin blood
levels are rarely available. From the studies, it is clear that
rare strains with diminished susceptibility to vancomycin
exist and may represent a single GISA/hGISA phenotype.
However, it cannot be concluded from most studies whether
hGISA was the cause of clinical failure or whether it devel-
oped during therapy in relation either to suboptimal dosing
of vancomycin or to the presence of foreign material. Lim-
ited data suggest that initial infection with GISA and hGISA
may be associated with poor outcome.
Resistance to new antimicrobial agents
Therapeutic alternatives for the treatment of infections with
GRE and MRSA with diminished susceptibility to glycopep-
tides are restricted to antibiotics introduced recently into
clinical practice, such as linezolid, tigecycline, and daptomy-
cin. However, these drugs are only approved for certain indi-
cations, and resistance has already been reported for some.
Tigecycline is a glycylcycline, derived from minocycline,
that overcomes the two major mechanisms of resistance to
tetracyclines, drug-speciﬁc efﬂux by pump acquisition and
ribosomal protection. This bacteriostatic antibiotic has a
wide spectrum of activity, and MIC90 values for enterococci
and staphylococci, including MDR isolates, are 0.12 or
0.25 mg/L [45]. Resistance in clinical isolates of staphylococci
has not been reported. However, mutants of MRSA N315
and Mu3 could be selected after 16 passages (MIC 4 mg/L)
[46]. Transcription analysis revealed a 100-fold increased
expression of a gene cluster, mepRAB, in mutants. The
mepRAB gene cluster encodes a MarR-like transcriptional reg-
ulator (mepR), a novel MATE family efﬂux pump (mepA), and
a hypothetical protein of unknown function (mepB). Muta-
tions in mepR presumably inactivated the MepR repressor.
Daptomycin is a bactericidal glycolipopeptide that has a
membrane-based mode of action involving calcium-dependent
membrane depolarization of and potassium release from
S. aureus. A model for the bactericidal action of daptomycin
involving oligomerization of daptomycin and disruption of the
functional integrity of the cytoplasmic membrane has been
proposed [47].
Daptomycin-resistant S. aureus and Enterococcus spp. have
been found during prolonged treatment with daptomycin
[48–50]. An association between glycopeptide-intermediate
S. aureus strains and diminished susceptibility to daptomycin
has been reported [51].
Although precise mechanisms have yet to be determined,
reduction of diffusion of daptomycin because of thickening of
cell walls induced by vancomycin has been proposed.
Whether this impacts on the efﬁcacy of daptomycin nega-
tively when this antibiotic is used in cases of failure of vanco-
mycin therapy is unknown.
Linezolid is the ﬁrst available oxazolidinone. This bacterio-
static antibiotic has a spectrum of activity limited to Gram-
positive organisms. Infrequent resistance caused by mutation
of the target site, the 23S rRNA, has been reported in
enterococci and staphylococci. Essentially, substitution of
guanine at position 2576 was observed in clinical isolates.
Most bacteria have several rRNA operon copies, the number
of which depends on the species (four to six in major Gram-
positive species). The level of resistance is proportional to
the number of mutated RNA operon copies.
As consumption of linezolid increased in the USA for the
treatment of GRE infections, it is not surprising that out-
breaks of E. faecalis and E. faecium resistant to linezolid were
reported [52].
The recent emergence in staphylococci of transferable
resistance to linezolid may be a major cause of concern.
Resistance is due to the cfr gene, which encodes an rRNA
methylase that transfers an additional methyl group to
A2503 in 23S rRNA. As several antibiotics share this same
nucleotide as a binding site, Cfr impairs ribosomal binding of
ﬁve different classes of antibiotics: phenicols, lincosamides,
oxazolidinones, pleuromutilins, and streptogramins A. This
resistance was ﬁrst reported in Staphylococcus spp. of animal
origin in Europe [53], and has recently been reported in
S. aureus and S. epidermidis from humans in Colombia and
the USA [54,55]. Comparison between the DNA sequences
surrounding cfr in animal S. aureus (pSCF53) and human
S. aureus (004-737X) as well as in S. epidermidis (426-3147L)
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isolates showed similarities that suggested genetic transfer
between strains from animals and humans [55].
In conclusion, bacteria have already selected some speciﬁc
ways to resist new antibiotics, i.e. efﬂux for tigecycline, cell
wall structure modiﬁcation for daptomycin, and ribosomal
target modiﬁcation for linezolid. So far, resistant isolates are
rare. However, a pessimistic point of view would be to say
that, because resistant isolates already exist, the lifespan of
the new antibiotics is already threatened. A more optimistic
point of view would be to say that the availability of several
antibiotic alternatives against MDR bacteria may delay the
spread of resistance. In addition, strict antibiotic usage pro-
tocols and hygiene precautions may delay the spread of
resistant microorganisms.
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